-
New Hope for HR+/HER2– Advanced Breast Cancer: postMONARCH Trial Results
Published on December 18, 2024 in the Journal of Clinical Oncology, the phase III postMONARCH trial presents compelling data on abemaciclib + fulvestrant for patients with advanced breast cancer who…
-
Reducing SOS Risk in R/R B-ALL Patients Undergoing Stem Cell Transplantation: A Collaborative Study
At the 2024 ASH Annual Meeting, Dr. Syed Osman Ahmed contributed to a study investigating the incidence of sinusoidal obstruction syndrome (SOS) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia…
-
ASCO 2024 | Breakthrough in Combined Therapy with Adebrelimab: Ushering in a New Era for Small Cell Lung Cancer Treatment in China
A phase II clinical study on the sequential use of Adebrelimab combined with chemotherapy followed by thoracic radiotherapy has garnered widespread attention at ASCO 2024, particularly for its impact on the treatment of extensive-stage small cell lung cancer (ES-SCLC).The results are striking: the regimen significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to…
-
CSCO BC | Academician Jinming Yu: Exploring New Directions in Breast Cancer Treatment and Empowering the Next Generation of Oncology Leaders
At the 2025 China National Breast Cancer Conference, CSCO President and Director of Shandong Cancer Hospital, Academician Jinming Yu, delivered a keynote address titled “Precision Integration of Radiotherapy and Immunotherapy in Breast Cancer.” His presentation explored not only the evolving role of radiotherapy in breast cancer treatment but also offered key insights into strengthening China’s…
-
Key Ingredients to Getting a Drug Combination Approved: Insights from Dr. Marjorie Green at ESMO TAT 2025
At ESMO TAT 2025, Dr. Marjorie Green, Senior Vice President and Head of Oncology at Merck, delivered a compelling presentation titled “Key Ingredients to Getting a Drug Combination Approved: Industry…
-
EBMT 2025 | Prof. Qingxiao Song: Breakthroughs in Steroid-Refractory GI-aGVHD and cGVHD
Prof. Qingxiao Song: At EBMT 2025, Professor Robert Zeiser from the University of Freiburg presented results from the STARGAZE trial—a multicenter, prospective Phase II study that, for the first time,…
-
EBMT 2025 | Prof. Yue Lu: CR and MRD Illuminate Prognosis in KMT2A-Rearranged Acute Leukemia
With the spring breeze of April sweeping through Florence, the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was successfully held from March 30…
-
EBMT 2025 | Prof. Yang Cao: Uncovering the Prognostic Impact of KRAS Mutations in KMT2A-Rearranged AML and Exploring Therapeutic Strategies
Prof. Yang Cao: KMT2A-rearranged acute myeloid leukemia (KMT2A-r AML), formerly known as MLL-rearranged AML, accounts for approximately 3% to 7% of newly diagnosed AML cases and represents a biologically and…
Connecting Medical Expertise through Media